| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
6.87(B) |
| Last
Volume: |
2,595,680 |
Avg
Vol: |
2,443,625 |
| 52
Week Range: |
$18.78 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 14.9 |
| Insider 6 Months : 16.6 |
| Insider 3/6 Months : 32 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
190,000 |
310,409 |
310,409 |
310,409 |
| Total Buy Value |
$3,932,734 |
$6,534,772 |
$6,534,772 |
$6,534,772 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
66,225 |
325,783 |
532,046 |
1,028,448 |
| Total Sell Value |
$1,469,691 |
$7,234,582 |
$11,431,100 |
$20,278,991 |
| Total People Sold |
2 |
4 |
5 |
11 |
| Total Sell Transactions |
2 |
8 |
12 |
26 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Haley Patrick J. |
EVP, Commercial |
• – – |
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
28,950 |
268,768 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2022-08-03 |
4 |
D |
$21.49 |
$154,234 |
D/D |
(7,177) |
622,804 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
28,950 |
629,981 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2022-08-03 |
4 |
D |
$21.49 |
$173,510 |
D/D |
(8,074) |
445,882 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
32,567 |
453,956 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2022-08-03 |
4 |
D |
$21.49 |
$154,234 |
D/D |
(7,177) |
418,135 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
28,950 |
425,312 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2022-08-03 |
4 |
D |
$21.49 |
$500,803 |
D/D |
(23,304) |
469,969 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2022-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
94,002 |
493,273 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2022-05-27 |
4 |
S |
$18.21 |
$342,567 |
D/D |
(18,812) |
239,818 |
|
16% |
|
| Freire Maria C |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
19,575 |
59,701 |
|
- |
|
| Poste George |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
19,575 |
193,189 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
19,575 |
292,767 |
|
- |
|
| Marchesi Vincent T |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
19,575 |
93,989 |
|
- |
|
| Wright Jacqueline |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,180 |
31,038 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
19,575 |
1,239,611 |
|
- |
|
| Feldbaum Carl B |
Director |
– • – |
2022-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,180 |
18,701 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2022-05-16 |
4 |
AS |
$20.07 |
$361,260 |
D/D |
(18,000) |
586,822 |
|
-22% |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2022-05-15 |
4 |
D |
$20.08 |
$107,408 |
D/D |
(5,349) |
601,031 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2022-05-15 |
4 |
D |
$20.08 |
$235,398 |
D/D |
(11,723) |
258,630 |
|
- |
|
| Lamb Peter |
EVP, Scientific Strategy & CSO |
• – – |
2022-05-15 |
4 |
D |
$20.08 |
$122,950 |
D/D |
(6,123) |
396,362 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2022-05-15 |
4 |
D |
$20.08 |
$169,556 |
D/D |
(8,444) |
421,389 |
|
- |
|
| Willsey Lance |
Director |
– • – |
2022-05-12 |
4 |
S |
$19.65 |
$786,000 |
D/D |
(40,000) |
424,415 |
|
16% |
|
| Willsey Lance |
Director |
– • – |
2022-05-12 |
4 |
OE |
$3.13 |
$125,200 |
D/D |
40,000 |
464,415 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2022-04-04 |
4 |
AS |
$23.00 |
$154,008 |
D/D |
(6,696) |
273,192 |
|
-16% |
|
985 Records found
|
|
Page 6 of 40 |
|
|
0.25 (1.14%) 
